Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Healthcare Biotechnology
Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Kane Biotech Inc > New Press Release - Kane Biotech Announces Health Canada Approval of revyve(TM) Antimicrobial Wound Gel
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(8)
•••
Comment by KevinOlearyon Nov 14, 2024 5:25pm
36 Views
Post# 36313706

RE:RE:New Press Release - Kane Biotech Announces Health Canada Approval of revyve(TM)&#xA0;Antimicrobial Wound Gel

RE:RE:New Press Release - Kane Biotech Announces Health Canada Approval of revyve(TM)&#xA0;Antimicrobial Wound GelThey don't need approval for the spray. They got a decision that was NR on July 23 about it, but the NR was technical so most people didn't understand all the ramifications of it. 
They had to send a batch of Revyve from the factory to Sweden for spray bottling, then it goes to the distributors. These processes take time, but it's going to be sold in 2024. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities